Last reviewed · How we verify
NCT03452956
Cognitive Impairement In Frontotemporal Dementia
trial testing None-Observation Only in Frontotemporal Degeneration in 997 participants. Completed in 15 July 2020.
15 July 2020
Quick facts
| Lead sponsor | University of Pennsylvania |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 997 |
| Start date | 1 July 2003 |
| Primary completion | 15 July 2020 |
| Estimated completion | 15 July 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- None-Observation Only
Conditions studied
- Frontotemporal Degeneration — all drugs for Frontotemporal Degeneration →
- Progressive Supranuclear Palsy — all drugs for Progressive Supranuclear Palsy →
- Multiple System Atrophy — all drugs for Multiple System Atrophy →
Sponsor
University of Pennsylvania
Who can join
18 and older, any sex, with Frontotemporal Degeneration or Progressive Supranuclear Palsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational study that aims to better understand the genetic causes of frontotemporal degeneration (FTD), Multiple Systems Atrophy (MSA), and Progressive Supranuclear Palsy (PSP). It is hoped the information gathered in this study will help lead to better diagnostics and future treatments.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03452956
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Frontotemporal Degeneration
Currently open trials in the same condition.
- NCT06604520 — Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia · Phase 2 · recruiting
- NCT06733714 — Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in · NA · recruiting
- NCT06395038 — IL-2 Plus Abatacept in FTD · Phase 1 · recruiting
- NCT06337578 — Advances in Telephone-based Cognitive Screening Procedures · recruiting
- NCT06122415 — The Swedish BioFINDER - Memory Clinic Study · recruiting
Other University of Pennsylvania trials
Trials by the same sponsor.
- NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
- NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
- NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
- NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
- NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03452956 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
- Last refreshed: 12 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03452956.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing